275 related articles for article (PubMed ID: 28886052)
1. Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathy.
Kong M; Kim SM; Ham DI
PLoS One; 2017; 12(9):e0184058. PubMed ID: 28886052
[TBL] [Abstract][Full Text] [Related]
2. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
3. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
4. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
5. Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy.
Kim YH; Lee B; Kang E; Oh J
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1711-1721. PubMed ID: 33417092
[TBL] [Abstract][Full Text] [Related]
6. Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
Ting DS; Ng WY; Ng SR; Tan SP; Yeo IY; Mathur R; Chan CM; Tan AC; Tan GS; Wong TY; Cheung CM
Am J Ophthalmol; 2016 Apr; 164():128-36.e1. PubMed ID: 26743619
[TBL] [Abstract][Full Text] [Related]
7. DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Chang YC; Cheng CK
Retina; 2020 Jul; 40(7):1403-1411. PubMed ID: 31181038
[TBL] [Abstract][Full Text] [Related]
8. Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.
Padrón-Pérez N; Arias L; Rubio M; Lorenzo D; García-Bru P; Català-Mora J; Caminal JM
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1119-1124. PubMed ID: 29490349
[TBL] [Abstract][Full Text] [Related]
9. Impact of sub-foveal choroidal thickness on clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy.
Venkatesh R; Gadde SGK; Pereira A; Singh V; Sangai S; Sridharan A; Bavaharan B; Jain N; Yadav NK
Int Ophthalmol; 2021 Jan; 41(1):87-97. PubMed ID: 32844237
[TBL] [Abstract][Full Text] [Related]
10. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Kim H; Lee SC; Kwon KY; Lee JH; Koh HJ; Byeon SH; Kim SS; Kim M; Lee CS
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1497-1503. PubMed ID: 26626772
[TBL] [Abstract][Full Text] [Related]
11. Subfoveal choroidal thickness change after intravitreal ranibizumab for idiopathic choroidal neovascularization.
Cao XS; Peng XY; You QS; Zhang YP; Jonas JB
Retina; 2014 Aug; 34(8):1554-9. PubMed ID: 24667570
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of pachyvessels in polypoidal choroidal vasculopathy.
Ijuin N; Tsujinaka H; Hirai H; Jimura H; Nakao S; Yamashita M; Nishi T; Ueda T; Ogata N
BMC Ophthalmol; 2020 Apr; 20(1):170. PubMed ID: 32349707
[TBL] [Abstract][Full Text] [Related]
13. CLINICAL RELEVANCE OF AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS IN POLYPOIDAL CHOROIDAL VASCULOPATHY.
Baek J; Lee JH; Lee WK
Retina; 2017 May; 37(5):943-950. PubMed ID: 27617539
[TBL] [Abstract][Full Text] [Related]
14. CHOROIDAL MORPHOLOGY IN EYES WITH POLYPOIDAL CHOROIDAL VASCULOPATHY AND NORMAL OR SUBNORMAL SUBFOVEAL CHOROIDAL THICKNESS.
Lee WK; Baek J; Dansingani KK; Lee JH; Freund KB
Retina; 2016 Dec; 36 Suppl 1():S73-S82. PubMed ID: 28005665
[TBL] [Abstract][Full Text] [Related]
15. Choroidal structures in polypoidal choroidal vasculopathy, neovascular age-related maculopathy, and healthy eyes determined by binarization of swept source optical coherence tomographic images.
Bakthavatsalam M; Ng DS; Lai FH; Tang FY; Brelén ME; Tsang CW; Lai TY; Cheung CY
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):935-943. PubMed ID: 28150038
[TBL] [Abstract][Full Text] [Related]
16. Analysis of choroidal thickness and vascularity in patients with unilateral polypoidal choroidal vasculopathy.
Lee K; Park JH; Park YG; Park YH
Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1157-1164. PubMed ID: 32037487
[TBL] [Abstract][Full Text] [Related]
17. POLYPOIDAL CHOROIDAL VASCULOPATHY FEATURES VARY ACCORDING TO SUBFOVEAL CHOROIDAL THICKNESS.
Jordan-Yu JM; Teo KYC; Chakravarthy U; Gan A; Tan ACS; Cheong KX; Wong TY; Cheung CMG
Retina; 2021 May; 41(5):1084-1093. PubMed ID: 32858669
[TBL] [Abstract][Full Text] [Related]
18. Peripapillary Choroidal Thickness Change of Polypoidal Choroidal Vasculopathy after Anti-vascular Endothelial Growth Factor.
Lee KH; Kim SH; Lee JM; Kang EC; Koh HJ
Korean J Ophthalmol; 2017 Oct; 31(5):431-438. PubMed ID: 28994269
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Anti-vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Clusters.
Chang YS; Kim JH; Kim JW; Lee TG; Kim CG
Korean J Ophthalmol; 2016 Aug; 30(4):272-9. PubMed ID: 27478354
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes in eyes with polypoidal choroidal vasculopathy with poor baseline visual acuity.
Kim JH; Kim JW; Lee TG; Lew YJ
J Ocul Pharmacol Ther; 2015 May; 31(4):241-7. PubMed ID: 25786032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
